Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Febit Establishes US Company

Published: Tuesday, August 15, 2006
Last Updated: Tuesday, August 15, 2006
Bookmark and Share
Febit launches the GENIOM biochip system in the US.

febit biotech gmbh has announced the establishment of febit Incorporation, a Delaware Company based in Medford, Boston/USA.

febit Inc. will be supporting all operations throughout America: in the US, Canada and the Southern American countries. With its presence in the Unites States, febit enters the largest market for biochip technology worldwide.

Thus, GENIOM sales and customer support will be handled by qualified stuff on site. All team members are experienced in the US market.

The knowledge transfer required for a start of febit Inc. was achieved by several months of prior training for technical specialists and the US management.

Temporary delegation of febit biotech gmbh staff is envisaged as well. A fully equipped application laboratory is already established that will enable customers to perform hands-on tests of their applications on the GENIOM system and develop assays in cooperation with febit Inc.

In addition, febit will offer workshops featuring various GENIOM applications. Production for the Americas (Northern and Southern America) is expected to take place in close cooperation with US-based companies.

febit Inc. is directed by Claus E. Schmidt, Vice President Operations & General Manager, an entrepreneur experienced in knowledge transfer between Europe and the USA.

In addition, he contributes expertise in the field of chemical engineering. febit Inc. CEO Cord F. Stahler directs febit biotech gmbh in Heidelberg as well and is an accomplished manager in the international biomedical technology business.

The Operative Management is completed by Stefan M. Matysiak, PhD, Director Customer Care, who is primarily responsible for customer care and the applications laboratory.

He has several years of experience in research and development, working for renowned companies and institutions in the US and Germany, such as Applied Biosystems Inc. and the German Cancer Research Center.

The Supervisory Board of febit Inc. - as the one of febit biotech gmbh - is chaired by Dr. Gerald Moller, Director of HBM BioCapital Management GmbH and former president and CEO of the Boehringer Mannheim Group.

Vice Chairman of the Supervisory Board is Michael Kranich, Director of DH-Capital GmbH & Co. KG and OH-Beteiligungen GmbH & Co. KG that holds the majority of febit biotech GmbH for the Hopp family.

Dietmar Hopp, co-founder of SAP and its CEO and Chairman for many years, is the most potent single investor of the German biotech industry.

He primarily invests in young, promising companies in that business such as febit biotech gmbh. Supporting febit´s establishment on the American continent, he expands his engagement in the fastest-growing biotech market.

Establishing a US-based company is a logical step for Cord F. Stahler, CEO of febit Inc, "After a successful start of GENIOM in the European market, penetration of the US as the largest biochip market is an essential move in our marketing strategy."

"We are confident that our US customers as well will be convinced by the unique speed and flexibility of our system in microarray synthesis and analysis."

"With a highly efficient team in the country, we are able to specifically address this market and successfully expand our business there."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Geniom Technology Applied to Targeted Next-Generation Sequencing
By enabling selective targeting, the Geniom® Biochip will allow researchers to sequence individual and well defined parts of genomes
Tuesday, July 24, 2007
Febit Achieves Sales Goals
Febit successfully markets the GENIOM bioanalysis device.
Thursday, March 16, 2006
Scientific News
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Genes That Increase Children's Risk Of Blood Infection Identified
A team led by Oxford University has identified genes that make certain children more susceptible to invasive bacterial infections by performing a large genome-wide association study in African children.
Poverty Marks a Gene, Predicting Depression
New study of high-risk teens reveals a biological pathway for depression.
World’s Largest Coral Gene Database
‘Genetic toolkit’ will help shed light on which species survive climate change.
Early Genetic Changes in Premalignant Colorectal Tissue Identified
Findings point to drivers of early cancer development, targets for cancer prevention therapies.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Modified Microalgae Converts Sunlight into Valuable Medicine
A special type of microalgae can soon produce valuable chemicals such as cancer treatment drugs and much more just by harnessing energy from the sun.
Breakthrough Approach to Breast Cancer Treatment
Scripps scientists have designed a drug candidate that decreases growth of breast cancer cells.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!